Thrivent Financial for Lutherans’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,451	Closed	-$161K	–	2309
2020 Q1	$161K	Buy	+10,451	New	+$227K	﹤0.01%	2157
2019 Q3	–	Sell	-67,430	Closed	-$875K	–	2243
2019 Q2	$875K	Buy	67,430 +21,397	+46%	+$274K	﹤0.01%	1499
2019 Q1	$560K	Buy	46,033 +1,016	+2%	+$13K	﹤0.01%	1741
2018 Q4	$513K	Buy	45,017 +161	+0.4%	+$2.6K	﹤0.01%	1550
2018 Q3	$974K	Sell	44,856 -5,413	-11%	-$113K	﹤0.01%	1297
2018 Q2	$888K	Buy	50,269 +272	+0.5%	+$5.52K	﹤0.01%	1333
2018 Q1	$1.05M	Buy	49,997 +647	+1%	+$12.6K	﹤0.01%	1211
2017 Q4	$715K	Hold	49,350	–	–	﹤0.01%	1446
2017 Q3	$779K	Hold	49,350	–	–	﹤0.01%	1312
2017 Q2	$613K	Hold	49,350	–	–	﹤0.01%	1398
2017 Q1	$802K	Hold	49,350	–	–	﹤0.01%	1292
2016 Q4	$744K	Hold	49,350	–	–	﹤0.01%	1301
2016 Q3	$752K	Buy	+49,350	New	+$2M	﹤0.01%	1258

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Thrivent Financial for Lutherans's ITCI Position: Q2 2020 in Review

Thrivent Financial for Lutherans sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2020, closing a stake of 10,451 shares — an estimated $161K sold.

Thrivent Financial for Lutherans first reported a position in ITCI in Q3 2016 and held it in 13 quarters. The position peaked at $1.05M in Q1 2018. 149 funds tracked by Wall St. Rank hold ITCI as of Q2 2020.

Thrivent Financial for Lutherans reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2020 after selling out during the quarter.
Thrivent Financial for Lutherans sold 10,451 Intra-Cellular Therapies Inc. shares in Q2 2020, an estimated $161K.
Thrivent Financial for Lutherans first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 13 quarters.
Thrivent Financial for Lutherans's Intra-Cellular Therapies Inc. position peaked at $1.05M in Q1 2018.
149 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2020.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2020, filed 12 Aug 2020.